Does the sympathetic nervous system contribute to the pathophysiology of metabolic syndrome?

Frontiers in Physiology

Volumn 6, Issue Aug, 2015, Pages

  Moreira, Marina C Santos ^a   Pinto, Izabella S Jesus ^a   Mourão, Aline A ^a   Fajemiroye, James O ^a   Colombari, Eduardo ^b   Reis, Ângela A Silva ^a   Freiria Oliveira, André H ^a   Ferreira Neto, Marcos L ^c   Pedrino, Gustavo R ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

Author keywords

Cardiovascular diseases; Central nervous system; Hypertension; Insulin resistance; Obesity

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL OBESITY; ADRENERGIC SYSTEM; ATHEROGENESIS; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; SYMPATHETIC TONE;

EID: 84941002599     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2015.00234     Document Type: Review

References (139)

1. Abboud, F. M. (1984). The sympathetic nervous system in hypertension. Clin. Exp. Hypertens. A 6, 43-60.
2. Abdellaoui, A., and Al-Khaffaf, H. (2007). C-reactive protein (CRP) as a marker in peripheral vascular disease. Eur. J. Vasc. Endovasc. Surg. 34, 18-22. doi: 10.1016/j.ejvs.2006.10.040
3. Alberti, K. G., and Zimmet, P. Z. (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15, 539-553.
4. Angelico, F., Alessandri, C., Ferro, D., Pignatelli, P., Del Ben, S., Fiorello, S., et al. (2006). Enhanced soluble CD40L in patients with the metabolic syndrome: relationship with in vivo thombin generation. Diabetologia 49, 1169-1174. doi: 10.1007/s00125-006-0222-7
5. Bahia, L., Aguiar, L. G., Villela, N., Bottino, D., Godoy-Matos, A. F., Geloneze, B., et al. (2006). Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome. Clin. Sci. 61, 433-440. doi: 10.1590/S1807-59322006000500010
6. Bauersachs, J., Bouloumié, A., Mülsch, A., Wiemer, G., Fleming, I., and Busse, R. (1998). Vasodilator dysfunction in aged spontaneously hypertensive rats: changes in NO synthase III and soluble guanylyl cyclase expression and in superoxide anion production. Cardiovasc. Res. 37, 772-779. doi: 10.1016/S0008-6363(97)00250-2
7. Beltowski, J., Wojcicka, G., Marciniak, A., and Jamroz, A. (2004). Oxidative stress, nitric oxide production, and renal sodium handling in leptininduced hypertension. Life Sci. 74, 2987-3000. doi: 10.1016/j.lfs.2003.10.029
8. Bertin, E., Nguyen, P., Guenounou, M., Durlach, V., Potron, G., and Leutenegger, M. (2000). Plasma levels of tumor necrosis factor-alpha (TNF-alpha) are essentially dependent on visceral fat amount in type 2 diabetic patients. Diabetes Metab. 26, 178-182.
9. Bianchi, C., Penno, G., Malloggi, L., Barontini, R., Corfini, M., Giovannitti, M. G., et al. (2008). Non-traditional markers of atherosclerosis potentiate the risk of coronary heart disease in patients with type 2 diabetes and metabolic syndrome. Nutr. Metab. Cardiovasc. Dis. 18, 31-38. doi: 10.1016/j.numecd.2006.07.007
10. Bouloumié, A., Curat, C. A., Sengenès, C., Lolmède, K., Miranville, A., and Busse, R. (2005). Role of macrophage tissue infiltration in metabolic diseases. Curr. Opin. Clin. Nutr. Metab. Care 8, 347-354. doi: 10.1097/01.mco.0000172571.41149.52
11. Brunner, E. J., Hemingway, H., Walker, B. R., Page, M., Clarke, P., Juneja, M., et al. (2002). Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation 106, 2659-2665. doi: 10.1161/01.CIR.0000038364.26310.BD
12. Campos, S. P., and Baumann, H. (1992). Insulin is a prominent modulator of cytokine-stimulated expression of acute-phase plasma protein genes. Mol. Cell. Biol. 12, 1789-1797.
13. Carvalho, M. H. C., Nigro, D., Lemos, V. S., Tostes, R. C. A., and Fortes, Z. B. (2001). Hypertension: the endothelium and its multiple functions. Rev. Bras. Hipertens. 8, 76-88.
14. Chen-Izu, Y., Chen, L., Bányász, T., McCulle, S. L., Norton, B., Scharf, S. M., et al. (2007). Hypertension-induced remodeling of cardiac excitation-contraction coupling in ventricular myocytes occurs prior to hypertrophy development. Am. J. Physiol. Heart Circ. Physiol. 293, H3301-H3310. doi: 10.1152/ajpheart.00259.2007
15. Cingolani, O. H., Yang, X.-P., Cavasin, M. A., and Carretero, O. A. (2003). Increased Systolic Performance with diastolic dysfunction in adult spontaneously hypertensive rats. Hypertension 41, 249-254. doi: 10.1161/01.HYP.0000052832.96564.0B
16. Contreras, R. J., Wong, D. L., Henderson, R., Curtis, K. S., and Smith, J. C. (2000). High dietary NaCl early in development enhances mean arterial pressure of adult rats. Physiol. Behav. 71, 173-181. doi: 10.1016/S0031-9384(00)00331-0
17. Côrtes, S. F., Andriantsitohaina, R., and Stoclet, J. C. (1996). Alterations of cyclo-oxygenase products and NO in responses to angiotensin II of resistance arteries from the spontaneously hypertensive rat. Br. J. Pharmacol. 119, 1635-1641. doi: 10.1111/j.1476-5381.1996.tb16083.x
18. da Costa Lima, N. K., Lima, F. B., dos Santos, E. A., Okamoto, M. M., Matsushita, D. H., Hell, N. S., et al. (1997). Chronic salt overload increases blood pressure and improves glucose metabolism without changing insulin sensitivity. Am. J. Hypertens. 10, 720-727. doi: 10.1016/S0895-7061(97)00090-3
19. Dampney, R. A. (1994). Functional organization of central pathways regulating the cardiovascular system. Physiol. Rev. 74, 323-364.
20. Dampney, R. A. L., Coleman, M. J., Fontes, M. A. P., Hirooka, Y., Horiuchi, J., Li, Y. W., et al. (2002). Central mechanisms underlying short-and long-term regulation of the cardiovascular system. Clin. Exp. Pharm. Physiol. 29, 261-268. doi: 10.1046/j.1440-1681.2002.03640.x
21. Dandona, P., Chaudhuri, A., Ghanim, H., and Mohanty, P. (2007). Proinflammatory effects of glucose and anti-inflammatory effects of insulin: relevance to cardiovascular disease. Am. J. Cardiol. 99(Suppl.), 15B-26B. doi: 10.1016/j.amjcard.2006.11.003
22. Dey, A., Allen, J., and Hankey-Giblin, P. A. (2015). Ontogeny and polarization of macrophages in inflammation: blood monocytes versus tissue macrophages. Front. Immunol. 5:683. doi: 10.3389/fimmu.2014.00683
23. Einhorn, D., Reaven, G. M., Cobin, R. H., Ford, E., Ganda, O. P., Handelsman, Y., et al. (2003). American College of Endocrinology position statement on the insulin resistance syndrome. Endocr. Pract. 9, 237-252.
24. Emdin, M., Gastaldelli, A., Muscelli, E., Macerata, A., Natali, A., Camastra, S., et al. (2001). Hyperinsulinemia and autonomic nervous system dysfunction in obesity: effects of weight loss. Circulation 103, 513-519. doi: 10.1161/01.CIR.103.4.513
25. Eriksson, J., Taimela, S., and Koivisto, V. A. (1997). Exercise and the metabolic syndrome. Diabetologia 40, 125-135. doi: 10.1007/s001250050653
26. Esler, M., Ferrier, C., Lambert, G., Eisenhofer, G., Cox, H., and Jennings, G. (1991). Biochemical evidence of sympathetic hyperactivity in human hypertension. Hypertension 17(Suppl.), III29-III35. doi: 10.1161/01.HYP.17.4_Suppl.III29
27. Esler, M., Rumantir, M., Wiesner, G., Kaye, D., Hasting, J., and Lambert, G. (2001). Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am. J. Hypertens. 14, 304s-309s. doi: 10.1016/S0895-7061(01)02236-1
28. Félétou, M., and Vanhoutte, P. M. (2006). Endothelium-derived hyperpolarizing factor: where are we now? Arterioscler. Thromb. Vasc. Biol. 26, 1215-1225. doi: 10.1161/01.ATV.0000217611.81085.c5
29. Ferrante, A. W. Jr. (2007). Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J. Intern. Med. 262, 408-414. doi: 10.1111/j.1365-2796.2007.01852.x
30. Ferreira, R. L., and Moisés, V. A. (2000). Importância da obesidade e da hipertensão arterial no desenvolvimento da hipertrofia do ventrículo esquerdo. Rev. Bras. Hipertens. 2, 156-160.
31. Festa, A., D'Agostino, R. Jr., Howard, G., Mykkänen, L., Tracy, R. P., and Haffner, S. M. (2000). Chronic sublinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102, 42-47. doi: 10.1161/01.CIR.102.1.42
32. Filho, A. G., Ferreira, A. J., Santos, S. H. S., Neves, S. R. S., Silva Camargos, E. R., Becker, L. K., et al. (2008). Selective increase of angiotensin(1-7) and its receptor in hearts of spontaneously hypertensive rats subjected to physical training. Exp. Physiol. 93, 589-598. doi: 10.1113/expphysiol.2007.041293
33. Fisher, J. P., and Paton, J. F. (2011). The sympathetic nervous system and blood pressure in humans: implications for hypertension. J. Hum. Hypertens. 26, 463-475. doi: 10.1038/jhh.2011.66
34. Francisco, G., Hernández, C., and Simó, R. (2006). Serum markers of vascular inflammation in dyslipidemia. Clin. Chim. Acta 369, 1-16. doi: 10.1016/j.cca.2005.12.027
35. Frontoni, S., Bracaglia, D., and Gigli, F. (2005). Relationship between autonomic dysfunction, insulin resistance and hypertension, in diabetes. Nutr. Metab. Cardiovasc. Dis. 15, 441-449. doi: 10.1016/j.numecd.2005.06.010
36. Frühbeck, G. (2002). Peripheral actions of leptin and its involvement in disease. Nutr. Rev. 60(10 Pt 2), S47-S55. doi: 10.1301/002966402320634931
37. Fujii, K., Tominaga, M., Ohmori, S., Kobayashi, K., Koga, T., Takata, Y., et al. (1992). Decreased endotheliumdependent hyperpolarization to acetylcholine in smooth muscle of mesenteric artery of spontaneously hypertensive rats. Circ. Res. 70, 660-669. doi: 10.1161/01.RES.70.4.660
38. Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., et al. (2004). Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114, 1752-1761. doi: 10.1172/JCI21625
39. Gordon, S. (2003). Alternative activation of macrophages. Nat. Rev. Immunol. 3, 23-35. doi: 10.1038/nri978
40. Gottlieb, M. G. V., Cruz, I. B. M., and Bodanese, L. C. (2008). Origin of the metabolic syndrome: genetic evolutionary and nutritional aspects. Sci. Med. 18, 31-38.
41. Grassi, G., and Seravalle, G. (2006). Autonomic imbalance and metabolic syndrome: unravelling interactions, mechanisms and outcomes. J. Hypertens. 24, 47-49. doi: 10.1097/01.hjh.0000198040.47128.4c
42. Grassi, G., Seravalle, G., Cattaneo, B. M., Bolla, G. B., Lanfranchi, A., Colombo, M., et al. (1995). Sympathetic activation in obese normotensive subjects. Hypertension 25, 560-563. doi: 10.1161/01.HYP.25.4.560
43. Grassi, G., Seravalle, G., Colombo, M., Bolla, G., Cattaneo, B. M., Cavagnini, F., et al. (1998). Body weight reduction sympathetic nerve traffic and arterial baroreflex in obese normotensive humans. Circulation 97, 2037-2042. doi: 10.1161/01.CIR.97.20.2037
44. Grassi, G., Seravalle, G., Dell'Oro, R., Turri, C., Bolla, G. B., and Mancia, G. (2000). Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 36, 538-542. doi: 10.1161/01.HYP.36.4.538
45. Grassi, G., Quarti-Trevano, F., Seravalle, G., and Dell'oro, R. (2007). Cardiovascular risk and adrenergic overdrive in the metabolic syndrome. Nutr. Metab. Cardiovasc. Dis. 17, 473-481. doi: 10.1016/j.numecd.2007.01.004
46. Gruen, M. L., Hao, M., Piston, D. W., and Hasty, A. H. (2007). Leptin requires canonical migratory signaling pathways for induction of monocyte and macrophage chemotaxis. Am. J. Physiol. Cell Physiol. 293, C1481-C1488. doi: 10.1152/ajpcell.00062.2007
47. Grundy, S. M., Brewer, H. B. Jr., Cleeman, J. I., Smith, S. C. Jr., and Lenfant, C. (2004). Definition of Metabolic syndrome: report of the national heart, lung, and blood institute/American heart association conference on scientific issues related to definition. Circulation 109, 433-438. doi: 10.1161/01.CIR.0000111245.75752.C6
48. Guyenet, P. G. (2006). The sympathetic control of blood pressure. Nat. Rev. Neurosci. 7, 335-346. doi: 10.1038/nrn1902
49. Guyenet, P. G., Koshiya, N., Huangfu, D., Baraban, S. C., Stornetta, R. L., and Li, Y. W. (1996). Role of medulla oblongata in generation of sympathetic and vagal outflows. Prog. Brain Res. 107, 127-144. doi: 10.1016/S0079-6123(08)61862-2
50. Gyawali, P., Takanche, J. S., Shrestha, R. K., Bhattarai, P., Khanal, K., Risal, P., et al. (2015). Pattern of thyroid dysfunction in patients with metabolic syndrome and its relationship with components of metabolic syndrome. Diabetes Metab. J. 39, 66-73. doi: 10.4093/dmj.2015.39.1.66
51. Hall, J. E., Brands, M. W., Hildebrandt, D. A., Kuo, J., and Fitzgerald, S. (2000). Role of sympathetic nervous system and neuropeptides in obesity hypertension. Braz. J. Med. Biol. Res. 33, 605-618. doi: 10.1590/S0100-879X2000000600001
52. Hayakawa, H., and Raij, L. (1998). Nitric oxide synthase activity and renal injury in genetic hypertension. Hypertension 31, 266-270.
53. Haynes, W. G., Morgan, D. A., Walsh, S. A., Mark, A. L., and Sivitz, W. I. (1997). Receptor-mediated regional sympathetic nerve activation by leptin. J. Clin. Invest. 100, 270-278. doi: 10.1172/JCI119532
54. He, F. J., Marrero, N. M., and Macgregor, G. A. (2008). Salt and blood pressure in children and adolescents. J. Hum. Hypertens. 22, 4-11. doi: 10.1038/sj.jhh.1002268
55. Head, G. A., Lim, K., Barzel, B., Burke, S. L., and Davern, P. J. (2014). Central nervous system dysfunction in obesity-induced hypertension. Curr. Hypertens. Rep. 16:466. doi: 10.1007/s11906-014-0466-4
56. Hemingway, H., Malik, M., and Marmot, M. (2001). Social and phychosocial influences on sudden cardiac death, ventricular arrhythmia and cardiac autonomic function. Eur. Heart J. 22, 1082-1101. doi: 10.1053/euhj.2000.2534
57. Hink, U., Li, H., Mollnau, H., Oelze, M., Matheis, E., Hartmann, M., et al. (2001). Mechanisms underlying endotelial dysfunction in diabetes mellitus. Circ. Res. 88, E14-E22. doi: 10.1161/01.RES.88.2.e14
58. Hsueh, W. A., and Law, R. (2003). The central role of fat and effect of peroxisome proliferator-activated and cardiovascular disease. Am. J. Cardiol. 92, 3-9. doi: 10.1016/S0002-9149(03)00610-6
59. Hung, J., McQuillan, B. M., Chapman, C. M. L., Thompson, P. L., and Beilby, J. P. (2005). Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler. Thromb. Vasc. Biol. 25, 1268-1273. doi: 10.1161/01.ATV.0000163843.70369.12
60. IDF. (2006). The IDF Consensus Worldwide Definition of the Metabolic Syndrome. Brussels: International Diabetes Federation.
61. Ito, S., Gordon, F. J., and Sved, A. F. (1999). Dietary salt intake alters cardiovascular responses evoked from the rostral ventrolateral medulla. Am. J. Physiol. 276, R1600-R1607.
62. Jamerson, K. A., Julius, S., Gudbrandsson, T., Andersson, O., and Brant, D. O. (1993). Refle sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 21, 618-623. doi: 10.1161/01.HYP.21.5.618
63. Kagota, S., Fukushima, K., Umetani, K., Tada, Y., Nejime, N., Nakamura, K., et al. (2010). Coronary vascular dysfunction promoted by oxidative-nitrative stress in SHRSP. Z-Lepr(fa) /IzmDmcr rats with metabolic syndrome. Clin. Exp. Pharmacol. Physiol. 37, 1035-1043. doi: 10.1111/j.1440-1681.2010.05432.x
64. Kang, K. (2014). Endothelium-derived relaxing factors of small resistance arteries in hypertension. Toxicol. Res. 30, 141-148. doi: 10.5487/tr.2014.30.3.141
65. Kassab, S., Kato, T., Wilkins, F. C., Chen, R., Hall, J. E., and Granger, J. P. (1995). Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 25(4 Pt 2), 893-897. doi: 10.1161/01.HYP.25.4.893
66. Kaur, J. (2014). A comprehensive review on metabolic syndrome. Cardiol. Res. Pract. 2014:943162. doi: 10.1155/2014/943162
67. Keaney, J. F., Larson, M. G., and Vasan, R. S. (2003). Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler. Thromb. Vasc. Biol. 23, 434-439. doi: 10.1161/01.ATV.0000058402.34138.11
68. Kern, P. A., Ranganathan, S., Li, C., Wood, L., and Ranganathan, G. (2001). Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. 280, E745-E751.
69. Kim, F., Pham, M., Luttrell, I., Bannerman, D. D., Tupper, J., Thaler, J., et al. (2007). Toll-like receptor-4 mediates vascular inflammation and insulin resistance in dietinduced obesity. Circ. Res. 100, 1589-1596. doi: 10.1161/CIRCRESAHA.106.142851
70. Kojda, G., Kottenberg, K., Hacker, A., and Noack, E. (1998). Alterations of the vascular and the myocardial soluble guanylate cyclase/ cGMP-system induced by long-term hypertension in rats. Pharm. Acta Helv. 73, 27-35.
71. Kon, K. K., Han, S. H., and Quon, M. J. (2005). Inflammatory markers and metabolic syndrome. J. Am. Coll. Cardiol. 46, 1978-1985. doi: 10.1007/s13410-012-0080-4
72. Laakso, M., Sarlund, H., and Mykkänen, L. (1990). Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis 10, 223-231. doi: 10.1161/01.ATV.10.2.223
73. Lakka, T. A., Laaksonen, D. E., Lakka, H.-M., Männikkö, N., Niskanen, L. K., Rauramaa, R., et al. (2003). Sedentary lifestyle, poor cardiorespiratory fitness, and the metabolic syndrome. Med. Sci. Sports Exerc. 35, 1279-1286. doi: 10.1249/01.MSS.0000079076.74931.9A
74. Landsberg, L., and Krieger, D. R. (1989). Obesity, metabolism and the sympathetic nervous system. Am. J. Hypertens. 2, 125S-132S.
75. Libby, P., Ridker, P. M., and Maseri, A. (2002). Inflammation and atherosclerosis. Circulation 105, 1135-1143. doi: 10.1161/hc0902.104353
76. Lopes, H. F., and Egan, B. M. (2006). Desequilíbrio autonômico e síndrome metabólica: parceiros patológicos em uma pandemia global emergente. Arq. Bras. Cardiol. 87, 538-547. doi: 10.1590/S0066-782X2006001700022
77. Luscher, T., and Vanhoutte, P. (1986). Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 8, 344-348.
78. Madden, C. J., and Sved, A. F. (2003). Rostral ventrolateral medulla C1 neurons and cardiovascular regulation. Cell Mol. Neurobiol. 23, 739-749. doi: 10.1023/A:1025000919468
79. Magni, P., Motta, M., and Martini, L. (2000). Leptin: a possible link between food intake, energy expenditure, and reproductive function. Regul. Pept. 92, 51-56.
80. Mancia, G., Grassi, G., Giannattasio, C., and Seravalle, G. (1999). Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 34(Pt 2), 724-728.
81. Mancia, G., Bousquet, P., Elghozi, J. L., Esler, M., Grassi, G., Julius, S., et al. (2007). The sympathetic nervous system and the metabolic syndrome. J. Hypertens. 25, 909-920. doi: 10.1097/HJH.0b013e328048d004
82. Mark, A. L. (2013). Selective leptin resistance revisited. Am. J. Physiol. Regul. Integr. Comp. Physiol. 305, R566-R581. doi: 10.1152/ajpregu.00180.2013
83. Martin, S. S., Qasim, A., and Reilly, M. P. (2008). Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J. Am. Coll. Cardiol. 52, 1201-1210. doi: 10.1016/j.jacc.2008.05.060
84. Martinez, F. O., Sica, A., Mantovani, A., and Locati, M. (2008). Macrophage activation and polarization. Front. Biosci. 13, 453-461. doi: 10.2741/2692
85. Martínez-Martínez, E., Jurado-López, R., Cervantes-Escalera, P., Cachofeiro, V., and Miana, M. (2014). Leptin, a mediator of cardiac damage associated with obesity. Horm. Mol. Biol. Clin. Invest. 18, 3-14. doi: 10.1515/hmbci-2013-0060
86. McIntyre, M., Bohr, D. F., and Dominiczak, A. F. (1999). Endothelial function in hypertension. The role of superoxide anion. Hypertension 34, 539-545. doi: 10.1161/01.HYP.34.4.539
87. Mendis, S., Davis, S., and Norrving, B. (2015). Organizational update: the world health organization global status report on noncommunicable diseases 2014; one more landmark step in the combat against stroke and vascular disease. Stroke 46, e121-e122. doi: 10.1161/STROKEAHA.115.008097
88. Mills, C. D., Thomas, A. C., Lenz, L. L., and Munder, M. (2014). Macrophage: SHIP of immunity. Front. Immunol. 5:620. doi: 10.3389/fimmu.2014.00620
89. Modan, M., and Halkin, H. (1991). Hyperinsulinemia or increased sympathetic drive as links for obesity and hypertension. Diabetes Care 14, 470-487.
90. Mohamed-Ali, V., Pinkney, J. H., and Coppack, S. W. (1998). Adipose tissue as an endocrine and paracrine organ. Int. J. Obes. Metab. Disord. 22, 1145-1158. doi: 10.1038/sj.ijo.0800770
91. Monami, M., Marchionni, N., Masotti, G., and Mannucci, E. (2007). IDF and ATP-III definitions of metabolic syndrome in the prediction of all-cause mortality in type 2 diabetic patients. Diabetes Obes. Metab. 9, 350-353. doi: 10.1111/j.1463-1326.2006.00615.x
92. Moreira, M. C., da Silva, E. F., Silveira, L. L., de Paiva, Y. B., de Castro, C. H., Freiria-Oliveira, A. H., et al. (2014). High sodium intake during postnatal phases induces an increase in arterial blood pressure in adult rats. Br. J. Nutr. 112, 1923-1932. doi: 10.1017/S0007114514002918
93. Nguyen, M. T., Favelyukis, S., Nguyen, A. K., Reichart, D., Scott, P. A., Jenn, A., et al. (2007). A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J. Biol. Chem. 282, 35279-35292. doi: 10.1074/jbc.M706762200
94. Northcott, J. M., Yeganeh, A., Taylor, C. G., Zahradka, P., and Wigle, J. T. (2012). Adipokines and the cardiovascular system: mechanisms mediating health and disease. Can. J. Physiol. Pharmacol. 90, 1029-1059. doi: 10.1139/y2012-053
95. Nuutila, P., Knuuti, M. J., Heinonen, O. J., Ruotsalainen, U., Teräs, M., Bergman, J., et al. (1994). Different alterations in the insulin-stimulated glucose uptake in the athlete's heart and skeletal muscle. J. Clin. Invest. 93, 2267-2274. doi: 10.1172/JCI117226
96. Oliveira-Sales, E. B., Toward, M. A., Campos, R. R., and Paton, J. F. (2014). Revealing the role of the autonomic nervous system in the development and maintenance of Goldblatt hypertension in rats. Auton. Neurosci. 183, 23-29. doi: 10.1016/j.autneu.2014.02.001
97. Palaniappan, L., Carnethon, M., and Fortmann, S. P. (2003). Association between microalbuminuria and the metabolic syndrome: Nhanes III. Am. J. Hypertens. 16, 952-958. doi: 10.1016/S0895-7061(03)01009-4
98. Perin, P. C., Maule, S., and Quadri, R. (2001). Sympathetic nervous system, diabetes, and hypertension. Clin. Exp. Hypertens. 23, 45-55. doi: 10.1081/CEH-100001196
99. Rahmouni, K. (2010). Leptin-induced sympathetic nerve activation: signaling mechanisms and cardiovascular consequences in obesity. Curr. Hypertens. Rev. 6, 104-209. doi: 10.2174/157340210791170994
100. Reaven, G. M. (1988). Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37, 1595-1607. doi: 10.2337/diab.37.12.1595
101. Reaven, G. M. (2003). Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J. Clin. Endocrinol. Metab. 88, 2399-2403. doi: 10.1210/jc.2003-030087
102. Rennie, K. L., McCarthy, N., Yazdgerdi, S., Marmot, M., and Brunner, E. (2003). Association of the metabolic syndrome with both vigorous and moderate physical activity. Int. J. Epidemiol. 32, 600-606. doi: 10.1093/ije/dyg179
103. Rexrode, K. M., Pradhan, A., Mansos, J. E., Buring, J. E., and Ridker, P. M. (2003). Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann. Epidemiol. 13, 1-9. doi: 10.1016/S1047-2797(03)00053-X
104. Roberts, C. K., Hevener, A. L., and Barnard, R. J. (2013). Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr. Physiol. 3, 1-58. doi: 10.1002/cphy.c110062
105. Rocchini, A. P., Key, J., Bondie, D., Chico, R., Moorehead, C., Katch, V., et al. (1989). The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N. Engl. J. Med. 321, 580-585. doi: 10.1056/NEJM198908313210905
106. Rodriguez-Iturbe, B., and Vaziri, N. D. (2007). Salt-sensitive hypertension-update on novel findings. Nephrol. Dial. Transplant. 22, 992-995. doi: 10.1093/ndt/gfl757
107. Roebuck, K. (1999). Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB. Int. J. Mol. Med. 4, 223-230. doi: 10.3892/ijmm.4.3.223
108. Ruan, H., and Lodish, H. F. (2003). Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alfa. Cytokine Growth Factor Rev. 14, 447-455. doi: 10.1016/s1359-6101(03)00052-2
109. Sacks, F. M., Svetkey, L. P., Vollmer, W. M., Appel, L. J., Bray, G. A., Harsha, D., et al. (2001). Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-Sodium collaborative research group. N. Engl. J. Med. 344, 3-10. doi: 10.1056/NEJM200101043440101
110. Salazar, M. R., Carbajal, H. A., Espeche, W. G., Dulbecco, C. A., Aizpurúa, M., Marillet, A. G., et al. (2011). Relationships among insulin resistance, obesity, diagnosis of the metabolic syndrome and cardio-metabolic risk. Diab. Vasc. Dis. Res. 8, 109-116. doi: 10.1177/1479164111403170
111. Shek, E. W., Brands, M. W., and Hall, J. E. (1998). Chronic leptin infusion increases arterial pressure. Hypertension 31(Pt 2), 409-414.
112. Shi, H., Kokoeva, M. V., Inouye, K., Tzameli, I., Yin, H., and Flier, J. S. (2006). TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 116, 3015-3025. doi: 10.1172/JCI28898
113. Skrapari, I., Tentolouris, N., Perrea, D., Bakoyiannis, C., Papazafiropoulou, A., and Katsilambros, N. (2007). Baroreflex sensitivity in obesity: relationship with cardiac autonomic nervous system activity. Obesity (Silver Spring) 15, 1685-1693. doi: 10.1038/oby.2007.201
114. Skyler, J. S., Marks, J. B., and Schneiderman, N. (1995). Hypertension in patients with diabetes mellitus. Am. J. Hypertens. 8(Pt 2), 100s-105s.
115. Stoian, M., and Stoica, V. (2014). The role of distubances of phosphate metabolism in metabolic syndrome. Medica 9, 255-260.
116. Sullivan, J. C., Pollock, D. M., and Pollock, J. S. (2002). Altered nitric oxide synthase 3 distribution in mesenteric arteries of hypertensive rats. Hypertension 39, 597-602. doi: 10.1161/hy0202.103286
117. Takeda, K., Kaisho, T., and Akira, S. (2003). Toll-like receptors. Annu. Rev. Immunol. 21, 335-376. doi: 10.1146/annurev.immunol.21.120601.141126
118. Tangvarasittichai, S. (2015). Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J. Diabetes 6, 456-480. doi: 10.4239/wjd.v6.i3.456
119. Tan, Z. Y., Lu, Y., Whiteis, C. A., Simms, A. E., Paton, J. F., Chapleau, M. W., et al. (2010). Chemoreceptor hypersensitivity, sympathetic excitation, and overexpression of ASIC and TASK channels before the onset of hypertension in SHR. Circ. Res. 106, 536-545. doi: 10.1161/CIRCRESAHA.109.206946
120. Tentolouris, N., Tsigos, C., Perea, D., Koukou, E., Kyriaki, D., Kitsou, E., et al. (2003). Differential effects of high-fat and high-carbohydrate isoenergetic meals on cardiac autonomic nervous system activity in lean and obese women. Metabolism 52, 1426-1432. doi: 10.1016/S0026-0495(03)00322-6
121. Tentolouris, N., Liatis, S., and Katsilambros, N. (2006). Sympathetic system activity in obesity and metabolic syndrome. Ann. N.Y. Acad. Sci. 1083, 129-152. doi: 10.1196/annals.1367.010
122. Thorp, A. A., and Schlaich, M. P. (2015). Relevance of sympathetic nervous system activation in obesity and metabolic syndrome. J. Diabetes Res. 2015:341583. doi: 10.1155/2015/341583
123. Toshima, S., Hasegawa, A., and Kurabayashi, M. (2000). Circulating oxidized low-density lipoprotein levels: a biochemical risk marker for coronary heart disease. Arterioscl. Thromb. Vasc. Biol. 20, 2243-2247. doi: 10.1161/01.ATV.20.10.2243
124. Traissac, P., Pradeilles, R., El Ati, J., Aounallah-Skhiri, H., Eymard-Duvernay, S., Gartner, A., et al. (2015). Abdominal vs. overall obesity among women in a nutrition transition context: geographic and socio-economic patterns of abdominal-only obesity in Tunisia. Popul. Health Metr. 13, 1. doi: 10.1186/s12963-015-0035-3
125. Tuck, M. (1992). Obesity, the sympathetic nervous system and essential hypertension. Hypertension 19, I67-I77. doi: 10.1161/01.HYP.19.1_Suppl.I67
126. Tumer, N., Erdos, B., Matheny, M., Cudykier, I., and Scarpace, P. J. (2007). Leptin antagonist reverses hypertension caused by leptin overexpression, but fails to normalize obesity-related hypertension. Hypertens. 25, 2471-2478. doi: 10.1097/HJH.0b013e3282e9a9fd
127. Van Guilder, G. P., Hoetzer, G. L., Greiner, J. J., Stauffer, B. L., and Desouza, C. A. (2006). Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity 14, 2127-2131. doi: 10.1038/oby.2006.248
128. Vanhala, P. T., Vanhala, M. J., Kumpusalo, E. A., and Takala, J. K. (2006). "Predictive value of different types of obesity on onset of metabolic syndrome; 5-years follow-up study," in Abstracts of the XIV International Symposium on Atherosclerosis (Rome), 1-591.
129. Vidonho, A. F. Jr., da Silva, A. A., Catanozi, S., Rocha, J. C., Beutel, A., Carillo, B. A., et al. (2004). Perinatal salt restriction: a new pathway to programming insulin resistance and dyslipidemia in adult wistar rats. Pediatr. Res. 56, 842-848. doi: 10.1203/01.PDR.0000145258.75160.5B
130. Virdis, A., Neves, M. F., Amiri, F., Viel, E., Touyz, R. M., and Schiffrin, E. L. (2002). Spironolactone improves angiotensininduced vascular changes and oxidative stress. Hypertension 40, 504-510. doi: 10.1161/01.HYP.0000034738.79310.06
131. Volp, A. C. P., Alfenas, R. C. G., Costa, N. M. B., Minim, V. P. R., Stringueta, P. C., and Bressan, J. (2008). [Inflammation biomarkers capacity in predicting the metabolic syndrome]. Arq. Bras. Endrocrinol. Metab. 52, 537-549.
132. Winkler, G., Kiss, S., Ketszthelyi, L., Sapi, Z., Ory, I., Salamon, F., et al. (2003). Expression of tumor necrosis factor (TNF)-alpha protein in the subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum TNF-alpha, soluble serum TNF-receptor-2 concentrations and C-peptide level. Eur. J. Endocrinol. 149, 129-135. doi: 10.1530/eje.0.1490129
133. WHO. (2013). A Global Brief on Hypertension. Geneva: World Health Organization.
134. WHO IDF. (2006). Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia. Technical Report Series, World Health Organization.
135. Wu, J. T., and Wu, L. L. (2006). Linking inflamation and atherogenesis: soluble markers identified for the detection of risk factors and for early risk assessment. Clin. Chim. Acta 366, 74-80. doi: 10.1016/j.cca.2005.10.016
136. Yoon, S., Assimes, T. L., Quertermous, T., Hsiao, C.-F., Chuang, L.-M., Hwu, C.-M., et al. (2014). Insulin resistance: regression and clustering. PLoS ONE 9:e94129. doi: 10.1371/journal.pone.0094129
137. Zeidan, A., Hunter, J. C., Javadov, S., and Karmazyn, M. (2011). mTOR mediates RhoA-dependent leptin-induced cardiomyocyte hypertrophy. Mol. Cell Biochem. 352, 99-108. doi: 10.1007/s11010-011-0744-2
138. Zile, M. R. (2002). New concepts in diastolic dysfunction and diastolic heart failure: part II: causal mechanisms and treatment. Circulation 105, 1503-1508. doi: 10.1161/hc1202.105290
139. Zubcevic, J., Waki, H., Raizada, M. K., and Paton, J. F. (2011). Autonomic-immune-vascular interaction: an emerging concept for neurogenic hypertension. Hypertension 57, 1026-1033. doi: 10.1161/HYPERTENSIONAHA.111.169748